To explore the concept of disrupted immune surveillance in NASH after anti-PD1 or anti-PDL1 treatment, we conducted a meta-analysis of three large randomized controlled phase III trials of immunotherapies in patients with advanced HCC (CheckMate-45911, IMbrave1505 and KEYNOTE-24010). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.